IP Library Granted Patent US 7,250,497
Granted Patent B2
US 7,250,497 · App. 10/457,839 · Granted Jul 31, 2007

Large deletions in human BRCA1 gene and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,250,497
App. No.
10/457,839
Granted
Jul 31, 2007
Kind
B2
Abstract

Large deletions have been identified in the BRCA1 gene in patients. The large deletions predispose the patients to breast cancer and ovarian cancer. Thus, methods for detecting the genetic variants are provided which can be used in detecting a predisposition to cancer.

Claims (20)

1. An isolated nucleic acid comprising SEQ ID NO:6, and the complement thereof.

2. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:37, or the complement thereof.

3. A method of making the isolated nucleic acid of claim 2 comprising amplifying genomic DNA isolated from a sample obtained from a human patient.

4. A method of making the isolated nucleic acid of claim 1 comprising amplifying genomic DNA isolated from a sample obtained from a human patient.

5. The method of claim 4 , wherein said sample is a blood sample.

6. The method of claim 4 , wherein said amplification is by the polymerase chain reaction.

7. The method of claim 4 , wherein said patient is being evaluated for an enhanced risk of cancer.

8. The method of claim 4 , wherein said cancer is breast or ovarian cancer.

9. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:38, or the complement thereof.

10. The isolated nucleic acid of claim 2 , wherein said isolated nucleic acid is a BRCA1 nucleic acid comprising SEQ ID NO:37.

11. A method of making the isolated nucleic acid of claim 9 comprising amplifying genomic DNA isolated from a sample obtained from a human patient.

12. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:39, or the complement thereof.

13. The isolated nucleic acid of claim 9 , wherein said isolated nucleic acid is a BRCA1 nucleic acid comprising SEQ ID NO:38.

14. A method of making the isolated nucleic acid of claim 12 comprising amplifying genomic DNA isolated from a sample obtained from a human patient.

15. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:40, or the complement thereof.

16. The isolated nucleic acid of claim 12 , wherein said isolated nucleic acid is a BRCA1 nucleic acid comprising SEQ ID NO:39.

17. A method of making the isolated nucleic acid of claim 15 comprising amplifying genomic DNA isolated from a sample obtained from a human patient.

18. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:41, or the complement thereof.

19. A method of making the isolated nucleic acid of claim 18 comprising amplifying genomic DNA isolated from a sample obtained from a human patient.

20. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid is a BRCA1 nucleic acid comprising SEQ ID NO:6.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 10, 2023
From: JPMORGAN CHASE BANK, N.A.
To: MYRIAD GENETICS, INC.; CRESCENDO BIOSCENCE, INC.; MYRIAD RBM, INC.; MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 064239/0091 →
SECURITY INTEREST Recorded Dec 27, 2016
From: MYRIAD GENETICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 041198/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2003
From: SCHOLL, THOMAS; HENDRICKSON, BRANT C.; WARD, BENJAMIN; PRUSS, DMITRY
To: MYRIAD GENETICS, INC.
Reel/Frame 014516/0464 →